Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Agata Makówka
Observed names:
A. Makówka,
Agata Makowka
Institution:
The Maria Sklodowska-Curie National Research Institute of Oncology
Observed institution:
The Maria Sklodowska-Curie National Research Institute of Oncology
ORCID:
0000-0001-5607-3047
Observed ORCID:
0000-0001-5607-3047
OpenAlex ID:
A5111041737
Interleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-Alpha
2025
·
Anna Borowiec
, Patrycja Ozdowska
, et al.
·
International Journal of Molecular Sciences
·
10
PDF
Prognostic value of coronary atherosclerosis and CAC score for the risk of chemotherapy-related cardiac dysfunction (CTRCD): The protocol of ANTEC study
2023
·
Anna Borowiec
, Patrycja Ozdowska
, et al.
·
PLoS ONE
·
10
PDF
Evaluation of the Prognostic Value of Obesity, Vitamin D Concentrations, and Systemic Inflammatory Response Indexes (SIRI, SII, PIV) in Patients With Breast Cancer Scheduled for Neoadjuvant Treatment
2025
·
Beata Kotowicz
, Malgorzata Fuksiewicz
, et al.
·
Breast Cancer Basic and Clinical Research
·
7
The importance of selected biomarkers in the clinical practice of breast cancer patients
2023
·
Agata Makówka
, Beata Kotowicz
·
Nowotwory Journal of Oncology
·
6
PDF
Neurofilaments as Prognostic Biomarkers in the Assessment of the Risk of Advanced Taxane-Induced Neuropathy in Breast Cancer Patients—A Pilot Study
2025
·
Agata Makówka
, Malgorzata Fuksiewicz
, et al.
·
Cancers
·
3
Baseline Galectin-3 in Patients with Breast Cancer Scheduled for Anthracycline Therapy: Associations with Cardiac Biomarkers, Left Ventricular Function, and HFA-ICOS Risk Stratification
2026
·
Anna Borowiec
, Patrycja Ozdowska
, et al.
·
International Journal of Molecular Sciences
Dynamic Changes in Apolipoproteins During Anthracycline Therapy: An Exploratory Study of Potential Biomarkers of Cardiotoxicity in Breast Cancer Patients
2026
·
Beata Puton
, Agata Makówka
, et al.
·
Journal of Clinical Medicine
160P Baseline IL-8 level as a predictive biomarker for anti-PD1 therapy in nonmelanoma skin cancers: Insights from a phase II agenonmela trial
2025
·
I. Lugowska
, A. Dawidowska
, et al.
·
ESMO Open
PDF
Show more works
View as search
Works count:
8
Citation count:
36
H-index:
4
I10-index:
2
Year
Topic
Type